Tag Archives: reimbursement
By Ben Comer | Published: September 28, 2011
R&D departments and payers need to communicate early in the drug development process: If pharma is a day late, then payers are likely to be a dollar short, according to panelists at the Galien Forum on Tuesday.
By Ben Comer | Published: September 23, 2011
Now that 90% of the top 43 countries for drug sales have instituted “significant” cost containment measures, it’s more important than ever to give payers the rest of the story, according to a Pfizer executive.
By Julian Upton | Published: March 25, 2011
The UK government’s proposals to introduce value-based pricing (VBP) — which aims to create a stronger link between the price the National Health Service pays for a medicine and the value it delivers (and in the process, ostensibly, further incentivize therapeutic innovation) — could actually serve to ‘hinder’ innovation, according to a UK think tank.
By Julian Upton | Published: December 1, 2010
The strict regulatory divide between market authorization and price reimbursement is crumbling in the US. Ansis Helmanis asks — is industry prepared to adapt or challenge? On September 17, the FDA and CMS jointly issued a Federal Register (FR) notice that they were establishing a process for overlapping evaluations of premarket, FDA-regulated medical products when [...]
By William Looney | Published: November 17, 2010
Can you manage the external market impact? Risk-sharing agreements – where companies contract with reimbursement or assessment authorities to guarantee a new drug’s performance, often against specific outcomes measures, in return for access to patients – are among the latest innovations in managing health care costs. Use of the tool is standard in Australia, is [...]